Skip to content
Influx Healthtech logo

Influx Healthtech

INFLUX NSE
₹262.35 No trade today
View as Markdown
MCP
Close 4 Nov 2026 ₹262.35 +64.30 +32.5% 1Y
Start ₹198.05

Key Fundamentals

SMEPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · TTM

ROCE
38.40%
Debt to Equity
0.00
EPS (TTM)
—
Book Value
₹43.52
Market Cap
—
P/E (TTM)
—
P/B
6.03
ROE
27.90%
Dividend Yield
0.00%
EBITDA
₹31.20 Cr
52W High
₹315.00
52W Low
₹170.75
Volume
0

Peer Comparison

Healthcare › Pharmaceuticals

Influx Healthtech peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Influx Healthtech (this company)
₹262.35—₹622 Cr6.030.00%27.90%38.40%——
Median 8 companies₹1,587.7038.81₹1,25,337 Cr5.400.44%17.40%19.15%₹28,324 Cr₹3,184 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

62 Good

Data confidence 84/100

Category scores

Quality
75
Strong
Returns, margins, earnings quality 22% weight
Valuation
22
Poor
Cheap vs sector & own history 24% weight
Growth
98
Strong
Sales & profit trajectory 9% weight
Financial Health
87
Strong
Solvency, leverage, coverage 9% weight
Momentum
34
Poor
Trend strength, vol-adjusted 12% weight
Ownership
79
Strong
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 37.8%

Weaknesses

2
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Working capital days have increased from 46.2 days to 77.8 days

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish865
OscillatorsBullish162
Moving AveragesStrong Bearish703

Key readings

RSI (14)
46.83
Neutral
MACD (12,26,9)
−2.52
Bullish
SMA (50)
274.40
Bearish
SMA (200)
255.19
Bullish

As of

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
5YZero base
3Y+24.60%
1Y+40.00%

Net profit

Net profit growth by window
5YZero base
3Y+44.22%
1Y+61.54%

Operating cash flow

Operating cash flow growth by window
5YZero base
3Y−17.02%
1Y−42.86%

Operating margin· change in pp

Operating margin growth by window
5YNo sales
3Y+5.94 pp
1Y+0.41 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2021₹0.00 Cr
Mar 2022₹59.00 Cr
Mar 2023₹76.00 Cr
Mar 2024₹100 Cr
Mar 2025₹105 Cr
Mar 2026₹147 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2021₹0.00 Cr
Mar 2022₹4.00 Cr
Mar 2023₹7.00 Cr
Mar 2024₹11.00 Cr
Mar 2025₹13.00 Cr
Mar 2026₹21.00 Cr

Half-yearly Results

₹ Cr
INFLUX half-yearly results, ₹ crore
Particulars Sep 2024Mar 2025Sep 2025Mar 2026
Sales
48
57
67
80
Expenses
39
45
52
65
Operating Profit
9
11
15
15
OPM %
19%
20%
22%
19%
Other Income
0
0
0
1
Interest
0
0
0
0
Depreciation
1
2
2
2
PBT
8
10
13
14
Tax %
27%
24%
23%
25%
Net Profit
6
8
10
11
EPS (₹)
3.1
4.21
4.32
4.56

Profit & Loss

₹ Cr
INFLUX profit and loss, annual, ₹ crore
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
0
59
76
100
105
147
Expenses
0
53
65
83
84
117
Operating Profit
0
6
11
17
21
30
OPM %
—
11%
14%
17%
20%
20%
Other Income
0
0
0
0
0
1
Interest
0
0
0
0
0
0
Depreciation
0
0
1
2
3
4
PBT
0
6
10
15
18
27
Tax %
—
26%
26%
25%
25%
25%
Net Profit
0
4
7
11
13
21
EPS (₹)
0
2.47
3.96
6.12
7.31
8.87
Div. Payout %
—
0%
0%
0%
0%
0%

Balance Sheet

₹ Cr
INFLUX balance sheet, annual, ₹ crore
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.03
0.03
0.03
0.03
18
23
Reserves
0
4
12
23
18
78
Borrowings
0
1
1
0
0
0
Other Liabilities
0
12
16
18
34
23
Total Liabilities
0
18
28
41
70
124
Fixed Assets
0
3
6
14
19
28
CWIP
0
0
0
0
0
3
Investments
0
0
0
0
0
2
Other Assets
0
15
22
27
52
90
Total Assets
0
18
28
41
70
124

Cash Flow

₹ Cr
INFLUX cash flow, annual, ₹ crore
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
4
7
9
7
4
Investing
0
−3
−5
−8
−9
−25
Financing
0
1
0
−1
0
45
Net Cash Flow
0
1
2
0
−2
23
Free Cash Flow
0
1
2
1
−1
−21
CFO/EBITDA
—
89
87
70
56
41

Ratios

INFLUX financial ratios, annual
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
—
64
66
58
113
84
Inventory Days
—
14
18
41
112
98
Days Payable
—
88
123
106
248
118
Cash Conversion Cycle
—
−10
−39
−6
−24
64
Working Capital Days
—
2
1
15
46
78
ROCE %
—
237%
111%
85%
60%
38%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Influx Healthtech insights

57 extracted metrics across FY21–FY26.

Shareholding Pattern

As of Sep 2026

  • Promoters 73.53%
  • Public 14.70%
  • DIIs 7.33%
  • Others 4.03%
  • FIIs 0.41%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Influx Healthtech

What does Influx Healthtech Ltd do?
Incorporated in 2020, Influx Healthtech Ltd is a CDMO which deals in nutraceuticals, Ready-to-Drink (RTD) beverages, functional nutrition and pet care.
Where is Influx Healthtech Ltd (INFLUX) listed?
Influx Healthtech Ltd trades as INFLUX on the NSE.
Which sector does Influx Healthtech Ltd belong to?
Influx Healthtech Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Influx Healthtech Ltd?
Over the last 52 weeks Influx Healthtech Ltd has traded between ₹170.75 and ₹315 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Influx Healthtech Ltd?
Influx Healthtech Ltd reported a return on equity of 27.90%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 2020, Influx Healthtech Ltd is a CDMO which deals in nutraceuticals, Ready-to-Drink (RTD) beverages, functional nutrition and pet care.

Website influxhealthtech.com
Listed 25 Jun 2025
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/INFLUX.md for Influx Healthtech Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month